Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

PR Newswire 23 hours ago

Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024

PR Newswire 5 days ago

Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin

PR Newswire 6 days ago

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Accesswire 12 days ago

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

PR Newswire April 18, 2024

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

PR Newswire April 10, 2024

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference

PR Newswire March 28, 2024

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

PR Newswire March 27, 2024

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML

PR Newswire March 27, 2024

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

PR Newswire March 25, 2024

Moleculin Reports Full Year 2023 Financial Results

PR Newswire March 22, 2024

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast

PR Newswire March 20, 2024

Moleculin Announces Reverse Stock Split

PR Newswire March 19, 2024

Moleculin to Present at the 36th Annual ROTH Conference

PR Newswire March 12, 2024

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3

PR Newswire January 24, 2024

Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

PR Newswire December 20, 2023

Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting

PR Newswire December 11, 2023

Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months

PR Newswire November 13, 2023

Moleculin Reports Third Quarter 2023 Financial Results

PR Newswire November 13, 2023

Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast

PR Newswire November 7, 2023